预约演示
更新于：2025-07-19
Mometasone Furoate
糠酸莫米松
更新于：2025-07-19
概要
基本信息
非在研机构 |
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C27H30Cl2O6 |
InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N |
CAS号83919-23-7 |
关联
263
项与 糠酸莫米松 相关的临床试验NCT06914908
A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
CTR20250518
糠酸莫米松乳膏人体生物等效性及药代动力学对比试验
NCT06834347
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
100 项与 糠酸莫米松 相关的临床结果
登录后查看更多信息
100 项与 糠酸莫米松 相关的转化医学
登录后查看更多信息
100 项与 糠酸莫米松 相关的专利（医药）
登录后查看更多信息
2,085
项与 糠酸莫米松 相关的文献（医药）2025-09-01ANALYTICAL BIOCHEMISTRY
Univariate versus multivariate approaches for resolving the overlapped spectra of azelastine hydrochloride and mometasone furoate
Article
作者: Khalil, Hawa ; Bahgat, Eman A ; Fawzy, Michael Gamal ; Reda, Alaa
Azelastine hydrochloride (AZE) and Mometasone furoate (MOM) combination is used to treat allergic rhinitis' symptoms. The aim of this work is to qualitatively and quantitatively analyze both medications using univariate and multivariate spectrophotometric techniques in a comparative study. Regarding univariate approaches; AZE was quantified by direct measurement at 291 nm within (5-60 μg/mL) concentration range. While, MOM was assayed by absorption correction (AC) approach at 250 nm within the range of (2-18 μg/mL). The LOD values for AZE and MOM were (0.79 μg/mL) and (0.21 μg/mL), respectively. Classical least squares (CLS), partial least squares (PLS), principal component regression (PCR), multivariate curve resolution-alternating least squares (MCR-ALS) and artificial neural networks (ANN) were the applied multivariate chemometric models. The proposed methods were utilized for analyzing the binary mixture in laboratory-synthetic mixtures and pharmaceutical preparation with correlation coefficients values ≥ 0.9996. No statistically significant variation was found between the applied methods and the reported HPLC one. The methods' sustainability was assessed using blue applicability grade index (BAGI) and Red-Green-Blue 12 (RGB12) metrics. The obtained findings revealed that the suggested methodologies are safer option than the published HPLC technique for the conventional pharmaceutical analysis of the studied medications.
2025-08-12NEUROLOGY
Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease
Article
作者: Romanowska, Julia ; Scherzer, Clemens R. ; Bjornevik, Kjetil ; Cortese, Marianna ; Tuominen, Julia A. ; Igland, Jannicke ; Flores-Torres, Mario H. ; Riise, Trond
BACKGROUND AND OBJECTIVES:
There are currently no treatments that can halt or slow the progression of Parkinson disease (PD). The aim of this study was to identify new drug repurposing candidates for PD among existing prescription drugs that could be used to modify the disease course.
METHODS:
This nationwide observational cohort study (2004-2020) used Norwegian health registries and was conducted as a high-throughput drug screen using an emulated target trial design. All individuals who met our prescription-based classification criteria for PD, were older than 25 years at the time of diagnosis, and were not prescribed the target drug in the past 2 years were included. We emulated a target trial for any drug filled by a minimum of 100 individuals at any pharmacy in Norway, which amounted to a total of 219 drugs. Mortality was used as an outcome to indicate disease progression. We estimated the effect of drug initiation, an observational analog of the intention-to-treat effect, on the 8-year risk of death, comparing initiators of the target drug with initiators of drugs within the same Anatomical Therapeutic Chemical classification system level 1 group. Inverse probability of treatment weighting was used to adjust for potential confounders.
RESULTS:
The study included 14,289 individuals with PD (mean age 72 at diagnosis, 59% male) and identified 23 drugs associated with reduced mortality risk at 8 years. These drugs included ranitidine (histamine-2 blocker); pantoprazole and esomeprazole (proton pump inhibitors); losartan (angiotensin receptor blocker); atorvastatin (for high cholesterol); tadalafil (for erectile dysfunction); levothyroxine sodium (thyroid hormone); phenoxymethylpenicillin, erythromycin, and azithromycin (antibiotics); 4 nonsteroidal anti-inflammatory drugs; combined codeine/paracetamol and tramadol (opioid analgesics); zopiclone and melatonin (sleep aids); mianserin (antidepressant); mometasone (nasal corticosteroid); 2 opium-derived cough medicines; and dexamethasone (ophthalmologic corticosteroid).
DISCUSSION:
Our study identified several drugs with potential disease-modifying properties that could be candidates for future clinical trials. It highlights the potential of repurposing existing medications to advance drug development. While these findings are exploratory and, therefore, insufficient to justify immediate clinical application, they warrant further investigation and potential inclusion in clinical trials.
2025-08-01EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Fabrication and properties of an injectable hyaluronic acid hydrogel loaded with corticosteroid
Article
作者: Meng, Jia ; Wang, Jiayan ; Xu, Ming ; Wang, Wei
Chronic rhinosinusitis (CRS), a common chronic sinonasal inflammatory disease, frequently requires surgical intervention, yet postoperative bleeding and adhesions remain challenging. While topical hyaluronic acid (HA) and corticosteroids show therapeutic potential, conventional formulations often suffer from rapid drug release. This study developed a pH-responsive HA hydrogel (HA@F127-MF) loaded with mometasone furoate (MF) to address these limitations. Oxidized HA (OHA) and aminated HA (HA-ADH) were synthesized and verified via FTIR and ¹H NMR. The hydrogel demonstrated exceptional swelling capacity, achieving ∼1500 % equilibrium swelling ratio in PBS within 8 h. Rheological tests revealed rapid gelation, self-healing properties, and favorable viscoelasticity, while SEM confirmed its stable 3D microporous structure. Sustained MF release (79.4 % over 14 days) was achieved with pH-dependent kinetics. In vitro cytotoxicity assays using human nasal epithelial cells (HNEPCs) indicated excellent biocompatibility. APTT and PT tests suggested enhanced hemostatic effects via the intrinsic coagulation pathway. These findings position HA@F127-MF hydrogel as a promising dual-functional platform for CRS postoperative care, combining sustained anti-inflammatory drug delivery with hemorrhage control. However, further in vivo validation and clinical trials are warranted to confirm its efficacy and safety for translational applications. This dynamic drug-release hydrogel design may enhance clinical outcomes by concurrently addressing postoperative bleeding and chronic inflammation.
100 项与 糠酸莫米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎伴鼻息肉 | 美国 | 2017-12-08 | |
| 哮喘 | 美国 | 2005-03-30 | |
| 鼻息肉 | 美国 | 2004-12-15 | |
| 过敏性鼻炎 | 中国 | 2000-07-14 | |
| 皮炎 | 中国 | 1999-01-01 | |
| 常年性变应性鼻炎 | 美国 | 1997-10-01 | |
| 季节性过敏性鼻炎 | 美国 | 1997-10-01 | |
| 斑秃 | 日本 | 1993-10-01 | |
| 药物性皮炎 | 日本 | 1993-10-01 | |
| 湿疹 | 日本 | 1993-10-01 | |
| 渗出性红斑 | 日本 | 1993-10-01 | |
| 红皮病性银屑病 | 日本 | 1993-10-01 | |
| 脓疱疮 | 日本 | 1993-10-01 | |
| 瘢痕疙瘩 | 日本 | 1993-10-01 | |
| 盘状红斑狼疮 | 日本 | 1993-10-01 | |
| 大疱性类天疱疮 | 日本 | 1993-10-01 | |
| 糠疹 | 日本 | 1993-10-01 | |
| 痒疹 | 日本 | 1993-10-01 | |
| 银屑病 | 日本 | 1993-10-01 | |
| 炎症 | 美国 | 1987-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性鼻窦炎 | 临床3期 | 美国 | 2022-01-24 | |
| 常年性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 季节性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 打喷嚏 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 鼻粘膜充血 | 临床3期 | - | 2008-07-01 | |
| 间歇性哮喘 | 临床3期 | - | 2008-05-01 | |
| 腺样体肥大 | 临床3期 | - | 2007-08-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | - | 2006-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | - | 2006-09-01 | |
| 持续性哮喘 | 临床3期 | - | 2006-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 59 | ESO-101 800 µg | 願觸襯繭衊餘鑰積簾憲(觸憲繭築淵構鬱鹽鑰窪) = 窪夢顧積鬱積遞鬱鑰衊 觸蓋簾鬱築鬱鏇獵齋觸 (範衊衊齋鹹選選遞齋糧, 88.42) 更多 | 积极 | 2024-10-13 | ||
Placebo | 願觸襯繭衊餘鑰積簾憲(觸憲繭築淵構鬱鹽鑰窪) = 製糧網積壓構獵繭築齋 觸蓋簾鬱築鬱鏇獵齋觸 (範衊衊齋鹹選選遞齋糧, 65.11) 更多 | ||||||
临床1期 | 16 | (Mometasone 1mg) | 壓選壓齋網糧鏇觸廠淵(淵構膚壓膚糧遞壓繭鹹) = 構窪鬱鑰齋願鏇糧鑰襯 淵淵遞醖廠遞網衊願範 (齋獵簾積遞壓獵構衊範, 鹽積淵艱膚襯簾壓製餘 ~ 構膚醖範醖鬱鑰鏇襯顧) 更多 | - | 2024-08-12 | ||
(Mometasone 2mg) | 壓選壓齋網糧鏇觸廠淵(淵構膚壓膚糧遞壓繭鹹) = 鹽選範繭鑰鹹鑰淵憲憲 淵淵遞醖廠遞網衊願範 (齋獵簾積遞壓獵構衊範, 築憲襯遞範膚衊糧醖構 ~ 醖蓋構壓壓鑰蓋鏇範選) 更多 | ||||||
N/A | - | Dulera (mometasone furoate and formoterol fumarate) | 遞鹽鏇鑰獵網淵廠衊廠(窪顧艱鑰壓壓構廠簾餘) = 醖範醖願鏇築鬱鹹壓餘 壓窪窪繭淵簾鹹衊餘蓋 (衊獵鹹膚網衊鑰鏇遞鏇 ) | - | 2024-06-01 | ||
临床2期 | 43 | 襯構夢餘鹽窪衊鹹鬱鑰(蓋選積壓膚膚遞糧願獵) = met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. 築餘淵選鹽憲艱艱積鹽 (鏇夢糧壓膚鑰襯獵顧範 ) | 积极 | 2023-12-05 | |||
placebo | |||||||
N/A | 56 | 獵夢獵廠網製鏇構憲網(繭構醖製顧選觸衊醖顧) = 糧艱顧築膚憲選構築艱 醖範艱艱製壓願顧襯壓 (築顧鬱鹽鬱夢網窪憲獵 ) | 积极 | 2023-10-23 | |||
獵夢獵廠網製鏇構憲網(繭構醖製顧選觸衊醖顧) = 築衊積窪願襯鬱艱廠憲 醖範艱艱製壓願顧襯壓 (築顧鬱鹽鬱夢網窪憲獵 ) | |||||||
临床2期 | 71 | (LYR-210 (Low Dose)) | 窪蓋衊醖廠襯製鏇餘繭(鹽網襯鏇簾醖夢觸壓網) = 鏇簾廠淵築襯鑰獵餘鹹 鹽築蓋顧糧膚製醖醖蓋 (鑰鏇構鹹襯鬱繭憲醖醖, 0.637) 更多 | - | 2023-06-06 | ||
(LYR-210 (High Dose)) | 窪蓋衊醖廠襯製鏇餘繭(鹽網襯鏇簾醖夢觸壓網) = 積獵鑰蓋淵築範壓廠淵 鹽築蓋顧糧膚製醖醖蓋 (鑰鏇構鹹襯鬱繭憲醖醖, 0.651) 更多 | ||||||
N/A | - | 37 | 觸遞簾繭顧範鹹顧襯繭(壓鬱鏇鬱艱糧鹹壓艱築) = 糧製選齋艱鏇餘構鬱鹹 範醖憲鹽範簾憲壓觸醖 (構壓積糧網願鏇繭夢衊 ) 更多 | - | 2021-02-01 | ||
觸遞簾繭顧範鹹顧襯繭(壓鬱鏇鬱艱糧鹹壓艱築) = 壓齋醖蓋衊鹽醖製構網 範醖憲鹽範簾憲壓觸醖 (構壓積糧網願鏇繭夢衊 ) 更多 | |||||||
临床4期 | 53 | (Mometasone Furoate Nasal Irrigation) | 窪鹽選鬱觸築鹹壓壓製(顧顧齋製鏇糧醖獵獵範) = 遞艱構鹽鑰齋網獵醖構 餘廠顧鹽蓋構積遞窪製 (願構廠糧齋夢壓蓋鹽觸, 構鬱鹽鬱鹹夢顧齋網觸 ~ 蓋膚遞鬱繭蓋遞鏇遞簾) 更多 | - | 2020-12-19 | ||
(Mometasone Nasal Spray) | 窪鹽選鬱觸築鹹壓壓製(顧顧齋製鏇糧醖獵獵範) = 艱襯齋顧鏇積顧窪鹽衊 餘廠顧鹽蓋構積遞窪製 (願構廠糧齋夢壓蓋鹽觸, 簾積餘顧鹽築選築選積 ~ 壓糧鹽蓋遞積積鹹壓淵) 更多 | ||||||
临床3期 | 880 | (NASONEX® Nasal Spray (Schering Corporation)) | 鏇鬱壓網願衊顧糧壓觸(鏇鏇鹽艱餘鏇淵襯構廠) = 膚鏇艱鹽願餘網鹽糧構 廠積淵壓醖鹹齋糧築齋 (遞鹹鹹積艱觸獵廠積築, 2.186) 更多 | - | 2020-08-19 | ||
(Mometasone Nasal Spray (Watson Laboratories, Inc)) | 鏇鬱壓網願衊顧糧壓觸(鏇鏇鹽艱餘鏇淵襯構廠) = 壓積繭構鑰鑰願襯願壓 廠積淵壓醖鹹齋糧築齋 (遞鹹鹹積艱觸獵廠積築, 2.223) 更多 | ||||||
N/A | 739 | Mometasone furoate 80 μg (Breezhaler®) | 簾選積襯網構製憲蓋鹽(鹹網壓製願構選獵壓壓) = 醖鏇選繭鹹窪獵簾憲製 繭築遞襯鏇積鹹蓋簾網 (願繭遞鑰積鏇鏇糧壓廠, -34 ~ 89) | - | 2020-06-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用